Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

Germaine Hanquet; Pavla Krizova; Tina Dalby; Shamez N. Ladhani; J. Pekka Nuorti; Kostas Danis; Jolita Mereckiene; Mirjam J. Knol; Brita A. Winje; Pilar Ciruela; Sara de Miguel; Maria Eugenia Portillo; Laura MacDonald; Eva Morfeldt; Jana Kozakova; Palle Valentiner-Branth; Norman K. Fry; Hanna Rinta-Kokko; Emmanuelle Varon; Mary Corcoran; Arie van der Ende; Didrik F. Vestrheim; Carmen Munoz-Almagro; Juan Carlos Sanz; Jesus Castilla; Andrew Smith; Birgitta Henriques-Normark; Edoardo Colzani; Lucia Pastore-Celentano; Camelia Savulescu

doi:10.3201/eid2801.210734

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

Germaine Hanquet^*, Pavla Krizova, Tina Dalby, Shamez N. Ladhani, J. Pekka Nuorti, Kostas Danis, Jolita Mereckiene, Mirjam J. Knol, Brita A. Winje, Pilar Ciruela, Sara de Miguel, Maria Eugenia Portillo, Laura MacDonald, Eva Morfeldt, Jana Kozakova, Palle Valentiner-Branth, Norman K. Fry, Hanna Rinta-Kokko, Emmanuelle Varon, Mary CorcoranArie van der Ende, Didrik F. Vestrheim, Carmen Munoz-Almagro, Juan Carlos Sanz, Jesus Castilla, Andrew Smith, Birgitta Henriques-Normark, Edoardo Colzani, Lucia Pastore-Celentano, Camelia Savulescu

^*Corresponding author for this work

Immunisation Hepatitis and Blood Safety

Research output: Contribution to journal › Article › peer-review

60 Citations (Scopus)

Abstract

We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution.Serotypes included in the 15- valent PCV represented one third of cases and those in the 20-valent PCVs two thirds of cases in children <5 years of age and in persons >65 years of age in 2018. Non-PCV13 serotype increases reduced the overall eff ect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.

Original language	English
Pages (from-to)	127-138
Number of pages	12
Journal	Emerging Infectious Diseases
Volume	28
Issue number	1
DOIs	https://doi.org/10.3201/eid2801.210734
Publication status	Published - Jan 2022

Bibliographical note

Publisher Copyright:
© 2022 Centers for Disease Control and Prevention (CDC). All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3201/eid2801.210734

Cite this

Hanquet, G., Krizova, P., Dalby, T., Ladhani, S. N., Nuorti, J. P., Danis, K., Mereckiene, J., Knol, M. J., Winje, B. A., Ciruela, P., de Miguel, S., Portillo, M. E., MacDonald, L., Morfeldt, E., Kozakova, J., Valentiner-Branth, P., Fry, N. K., Rinta-Kokko, H., Varon, E., ... Savulescu, C. (2022). Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe. Emerging Infectious Diseases, 28(1), 127-138. https://doi.org/10.3201/eid2801.210734

@article{cd45833aac3c4389b1cecfe1493c8fb8,

title = "Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe",

abstract = "We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution.Serotypes included in the 15- valent PCV represented one third of cases and those in the 20-valent PCVs two thirds of cases in children <5 years of age and in persons >65 years of age in 2018. Non-PCV13 serotype increases reduced the overall eff ect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.",

author = "Germaine Hanquet and Pavla Krizova and Tina Dalby and Ladhani, {Shamez N.} and Nuorti, {J. Pekka} and Kostas Danis and Jolita Mereckiene and Knol, {Mirjam J.} and Winje, {Brita A.} and Pilar Ciruela and {de Miguel}, Sara and Portillo, {Maria Eugenia} and Laura MacDonald and Eva Morfeldt and Jana Kozakova and Palle Valentiner-Branth and Fry, {Norman K.} and Hanna Rinta-Kokko and Emmanuelle Varon and Mary Corcoran and {van der Ende}, Arie and Vestrheim, {Didrik F.} and Carmen Munoz-Almagro and Sanz, {Juan Carlos} and Jesus Castilla and Andrew Smith and Birgitta Henriques-Normark and Edoardo Colzani and Lucia Pastore-Celentano and Camelia Savulescu",

year = "2022",

month = jan,

doi = "10.3201/eid2801.210734",

language = "English",

volume = "28",

pages = "127--138",

journal = "Emerging Infectious Diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "1",

}

Hanquet, G, Krizova, P, Dalby, T, Ladhani, SN, Nuorti, JP, Danis, K, Mereckiene, J, Knol, MJ, Winje, BA, Ciruela, P, de Miguel, S, Portillo, ME, MacDonald, L, Morfeldt, E, Kozakova, J, Valentiner-Branth, P, Fry, NK, Rinta-Kokko, H, Varon, E, Corcoran, M, van der Ende, A, Vestrheim, DF, Munoz-Almagro, C, Sanz, JC, Castilla, J, Smith, A, Henriques-Normark, B, Colzani, E, Pastore-Celentano, L & Savulescu, C 2022, 'Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe', Emerging Infectious Diseases, vol. 28, no. 1, pp. 127-138. https://doi.org/10.3201/eid2801.210734

TY - JOUR

T1 - Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

AU - Hanquet, Germaine

AU - Krizova, Pavla

AU - Dalby, Tina

AU - Ladhani, Shamez N.

AU - Nuorti, J. Pekka

AU - Danis, Kostas

AU - Mereckiene, Jolita

AU - Knol, Mirjam J.

AU - Winje, Brita A.

AU - Ciruela, Pilar

AU - de Miguel, Sara

AU - Portillo, Maria Eugenia

AU - MacDonald, Laura

AU - Morfeldt, Eva

AU - Kozakova, Jana

AU - Valentiner-Branth, Palle

AU - Fry, Norman K.

AU - Rinta-Kokko, Hanna

AU - Varon, Emmanuelle

AU - Corcoran, Mary

AU - van der Ende, Arie

AU - Vestrheim, Didrik F.

AU - Munoz-Almagro, Carmen

AU - Sanz, Juan Carlos

AU - Castilla, Jesus

AU - Smith, Andrew

AU - Henriques-Normark, Birgitta

AU - Colzani, Edoardo

AU - Pastore-Celentano, Lucia

AU - Savulescu, Camelia

PY - 2022/1

Y1 - 2022/1

N2 - We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution.Serotypes included in the 15- valent PCV represented one third of cases and those in the 20-valent PCVs two thirds of cases in children <5 years of age and in persons >65 years of age in 2018. Non-PCV13 serotype increases reduced the overall eff ect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.

AB - We evaluated invasive pneumococcal disease (IPD) during 8 years of infant pneumococcal conjugate vaccine (PCV) programs using 10-valent (PCV10) and 13-valent (PCV13) vaccines in 10 countries in Europe. IPD incidence declined during 2011-2014 but increased during 2015-2018 in all age groups. From the 7-valent PCV period to 2018, IPD incidence declined by 42% in children <5 years of age, 32% in persons 5-64 years of age, and 7% in persons >65 years of age; non-PCV13 serotype incidence increased by 111%, 63%, and 84%, respectively, for these groups. Trends were similar in countries using PCV13 or PCV10, despite different serotype distribution.Serotypes included in the 15- valent PCV represented one third of cases and those in the 20-valent PCVs two thirds of cases in children <5 years of age and in persons >65 years of age in 2018. Non-PCV13 serotype increases reduced the overall eff ect of childhood PCV10/PCV13 programs on IPD. New vaccines providing broader serotype protection are needed.

UR - http://www.scopus.com/inward/record.url?scp=85121727482&partnerID=8YFLogxK

U2 - 10.3201/eid2801.210734

DO - 10.3201/eid2801.210734

M3 - Article

C2 - 34932457

AN - SCOPUS:85121727482

SN - 1080-6040

VL - 28

SP - 127

EP - 138

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

IS - 1

ER -

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this